Evidence map›Paper›PMID 38755510›Full record

ArticleCardiovascular intervention and therapeutics2024

Impact of osteoporotic risk in men undergoing transcatheter aortic valve replacement: a report from the LAPLACE-TAVI registry.

Takashi Funaki, Mike Saji, Ryosuke Higuchi, Itaru Takamisawa, Mamoru Nanasato, Harutoshi Tamura, Kei Sato, Hiroaki Yokoyama, Shinichiro Doi, Shinya Okazaki and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Cardiovascular intervention and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takashi FunakiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. mikesaji8@gmail.com.ORCID http://orcid.org/0000-0003-2057-109X
Ryosuke HiguchiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Itaru TakamisawaDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mamoru NanasatoDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Harutoshi TamuraDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Kei SatoDepartment of Cardiology and Nephrology, Mie University Graduate School of Medicine, Mie, Japan.
Hiroaki YokoyamaDepartment of Cardiology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Shinichiro DoiDepartment of Cardiovascular Biology and Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Shinya OkazakiDepartment of Cardiovascular Biology and Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Takayuki OnishiDepartment of Cardiology, Kawasaki Saiwai Hospital, Kanagawa, Japan.
Tetsuya TobaruDepartment of Cardiology, Kawasaki Saiwai Hospital, Kanagawa, Japan.
Shuichiro TakanashiDepartment of Cardiology Surgery, Kawasaki Saiwai Hospital, Kanagawa, Japan.
Takanori IkedaDevision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, 6-11-1 Omori-Nishi, Otaku, Tokyo, 143-8541, Japan.
Hiroaki KitaokaDepartment of Cardiology and Geriatrics, Kochi University, Kochi, Japan.
Mitsuaki IsobeSakakibara Heart Institute, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low body weight and advanced age are among the best predictors of osteoporosis. Osteoporosis Self-Assessment Tool (OST) values are calculated by a simple formula [(body weight in kilograms - age in years) × 0.2] to identify patients at increased risk of osteoporosis. In our recent single-center study, we demonstrated an association between OST and poor outcomes in postmenopausal women after transcatheter aortic valve replacement (TAVR). We aimed to investigate the impact of osteoporotic risk in men with aortic stenosis who underwent TAVR in a large cohort. In this multi-center study, 1,339 men who underwent TAVR between April 2010 and July 2023 were retrospectively analyzed. Women were excluded from the present study. All patients were deemed appropriate for TAVR after a review by a multidisciplinary team. Baseline characteristics of patients were compared by dividing patients into three tertiles, based on the OST value: ≤ - 6.16, - 6.16 to - 4.14, and - 4.14 < for tertiles 1, 2, and 3, respectively. Primary endpoint was all-cause mortality after TAVR. Tertile 1 (patients with the lowest OST values) included older patients with smaller body mass index, lower hemoglobin and albumin levels. In addition, they had greater clinical frailty scale, slower 5-meter walk test, weaker hand grip strength, and more cognitive impairment, indicating increased frailty. They were more severely symptomatic, with lower ejection fractions, smaller aortic valve areas, and more tricuspid regurgitation than were patients in the other two groups. Multivariate analysis revealed that OST tertiles 3 was associated with decreased risk of all-cause mortality (hazard ratio, 0.66; 95% confidence interval, 0.48-0.90), compared with OST tertile 1 as a reference. For OST tertiles 1, 2, and 3, the estimated 1-year survival rates of all-cause mortality post-TAVR were 83.6% ± 1.9%, 91.1% ± 1.4%, and 93.1% ± 1.3%, respectively, (log-rank, p < 0.001). In conclusions, in men as same as women, osteoporotic risk assessed by OST values was overlapped with increased frailty. The simple OST formula was useful for predicting all-cause mortality in patients undergoing TAVR in large registry datasets.

Indexed as

Aortic Valve StenosisOsteoporosisRegistriesTranscatheter Aortic Valve ReplacementAgedAged, 80 and overHumansMaleRetrospective StudiesRisk AssessmentRisk FactorsOsteoporosisTAVITAVR

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.